TPIV 100

Drug Profile

TPIV 100

Alternative Names: TPIV-100

Latest Information Update: 21 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mayo Clinic
  • Developer Mayo Clinic; TapImmune
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Breast cancer

Most Recent Events

  • 21 Nov 2017 Phase Ib/IIa trial is planned in Breast cancer
  • 15 Nov 2017 Mayo Clinic plans a phase Ib/IIa trial in Breast cancer (HER2/neu+ ductal carcinoma in situ) in 1H 2018
  • 07 Jun 2016 TapImmune exercises its option agreement and in-licenses worldwide rights to HER2neu vaccine technology from Mayo Clinic
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top